Morbidity, mortality and quality of life in the ageing haemodialysis population: results from the ELDERLY study

Joerg Seckinger¹,², Wilfried Dschietzig³, Gerd Leimenstoll⁴, Peter M. Rob⁵, Martin K. Kuhlmann⁶, Wolfgang Pommer⁷, Uwe Fraass⁸, Eberhard Ritz² and Vedat Schwenger²,⁹

¹Division of Nephrology, Department of Internal Medicine, Zug Cantonal Hospital, Landhausstrasse 11, 6340 Baar, Switzerland, ²Division of Nephrology, Department of Internal Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 162, 69120 Heidelberg, Germany, ³Nephrologicum Lausitz, Ambulantes Zentrum fuer Nieren- und Hochdruckerkrankungen, Cottbus, Germany, ⁴Nieren- und Gefaesszentrum Kiel, Ambulanz fuer Nieren- und Hochdruckerkrankungen, Dialyse und Transplantationsmedizin, Kiel, Germany, ⁵Sana Kliniken Luebeck, Nierenzentrum, Luebeck, Germany, ⁶Division of Nephrology, Department of Internal Medicine, Vivantes Klinikum im Friedrichshain, Berlin, Germany, ⁷KfH Kuratorium fuer Dialyse und Nierentransplantation e.V., Bildungszentrum, Neu-Isenburg, Germany, ⁸Amgen GmbH, Munich, Germany and ⁹Department of Nephrology, Klinikum Stuttgart, Stuttgart, Germany

Correspondence and offprint requests to: Joerg Seckinger; E-mail: jsecking@ix.urz.uni-heidelberg.de

Abstract

Background: The physical–functional and social–emotional health as well as survival of the elderly (≥75 years of age) haemodialysis patient is commonly thought to be poor. In a prospective, multicentre, non-interventional, observational study, the morbidity, mortality and quality of life (QoL) in this patient group were examined and compared with a younger cohort.

Methods: In 92 German dialysis centres, 2507 prevalent patients 19–98 years of age on haemodialysis for a median of 19.2 months were included in a drug monitoring study of darbepoetin alfa. To examine outcome and QoL parameters, 24 months of follow-up data in the age cohorts <75 and ≥75 years were analysed. Treatment parameters, adverse and intercurrent events, hospitalizations, morbidity and mortality were assessed. QoL was evaluated by means of the 47-item Functional Assessment of Chronic Illness Therapy–Anaemia score (FACT-An, version 4).

Results: The 2-year mortality rate was 34.7% for the older cohort and 15.8% for the younger cohort. The mortality rate for the haemodialysed elderly patients was 6.2% higher in absolute value compared with the age-matched background population. A powerful predictor of survival was the baseline FACT-An score and a close correlation with the 20-item anaemia subscale (AnS) was demonstrated. While the social QoL in the elderly patients was more stable than in the younger cohort (leading to equivalent values at the end of the study period), a pronounced deterioration of physical and functional status was observed.

Received: August 28, 2015. Accepted: July 27, 2016

© The Author 2016. Published by Oxford University Press on behalf of ERA-EDTA.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
The median number of all-cause hospital days per patient-year was 12.3 for the elderly cohort and 8.9 for the younger patient population. The overall 24-month hospitalization rate was only marginally higher in the elderly cohort (34.0 versus 33.3%).

**Conclusions:** In this observational study, the mortality rate of elderly haemodialysis patients was not exceedingly high compared with the age-matched background population. Furthermore, the hospitalization rate was only slightly higher compared with the younger age group and the median yearly hospitalization time trended lower compared with registry data. The social well-being of elderly haemodialysis patients showed a less pronounced decline over time and was equal to the score of the younger cohort at the end of the study period. The physical and functional status in the elderly patients was lower and showed a sharper decline over time. The baseline FACT-An score correlated closely with the 24-month survival probability.

**Key words:** chronic haemodialysis, elderly, quality of life, survival analysis, vascular access

### Introduction

The dialysis population is growing and ageing. All major renal registries have reported a steady increase in the proportion of elderly patients (≥75 years old) requiring renal replacement therapy (RRT) [1–4]. According to records from the United States Renal Data System (USRDS), the adjusted incident rate of end-stage renal disease (ESRD) has grown ∼12% for patients ≥75 years of age since the year 2000. The average age of incident ESRD patients was 63 years in the 2009 cohort and 25% of patients were ≥75 years of age (mean age 82 years) [1]. Despite the high rate of cause-specific mortality in elderly patients with chronic kidney disease, a significant percentage progress to ESRD, underlining the importance of adequate nephrological care [5, 6]. Relatively poor functional status and outcomes have been reported for elderly haemodialysis patients, especially in negatively selected cohorts [7, 8]. USRDS statistics reveal that the expected remaining lifetime of an individual ≥75 years of age on RRT is ≤3.1 years but ≤8.8 years for the background population. Similar results are reported from the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) registry (≤3.4 versus ≤11.3 years). According to USRDS data, the adjusted 2-year and 5-year survival rates for incident ESRD patients are as low as 41 and 13% (51 and 19% for ERA-EDTA data), respectively [1, 2]. The predominant treatment modality for incident and prevalent elderly ESRD patients is in-centre haemodialysis, while other modalities are reported with <5% for incident and <12% for prevalent patients [1]. To date there are only limited data on the determinants of survival, the degree of physical–functional fitness and social–emotional well-being of elderly haemodialysis patients, and there have been intense discussions about whether the expensive and resource-consuming procedure of haemodialysis is justified by acceptable outcomes and quality of life (QoL) in the elderly.

### Materials and methods

**Study design**

In a prospective, longitudinal, nationwide, non-randomized study of haemodialysis patients receiving darbepoetin alfa (92 dialysis centers in different regions of Germany), QoL and treatment parameters, adverse and intercurrent events, hospitalizations, morbidity and mortality were assessed in the age groups ≥75 and <75 years. The patients were followed up for a period of 24 months. The ELDERLY project was sponsored by Amgen and was approved by national authorities. All included patients provided written, informed consent. The study was conducted in compliance with local ethical guidelines and the Declaration of Helsinki. All data were evaluated by an independent biostatistician.

### Study patients, data collection and definitions

Non-critically ill patients receiving in-centre haemodialysis for >3 months along with concomitant darbepoetin alfa therapy for the treatment of anaemia were eligible for the study. Baseline characteristics (see Table 1) were assessed at the time of enrolment and patients were then prospectively monitored using an observational plan. Adverse events and changes of darbepoetin alfa dose were continuously monitored. Dialysis parameters, BIOM (kg/m²),

| Table 1. Baseline demographic dataa |
|-----------------------------------|
| Age (years)                        | Age <75 years | Age ≥75 years |
| Mean ± SD                         | 62.5 ± 10.6   | 80.2 ± 3.9    |
| 95% CI for the mean               | 62.0–63.0     | 79.9–80.4     |
| Sex, n (%)                        |               |               |
| Male                              | 1003 (58.6)   | 374 (47.0)    |
| Female                            | 708 (41.4)    | 422 (53.0)    |
| Dialysis vintage (months)         |               |               |
| Median                            | 20.9          | 15.9          |
| 95% CI for the median             | 18.9–33.7     | 14.0–18.7     |
| Vascular access, %                |               |               |
| Arteriovenous fistula             | 86.4          | 81.2          |
| Arteriovenous graft               | 11.4          | 14.7          |
| Catheter                          | 2.2           | 4.1           |
| Underlying disease, %             |               |               |
| Diabetic nephropathy              | 31.6          | 32.7          |
| Chronic glomerular nephritis      | 20.7          | 12.3          |
| Vascular nephropathy              | 13.6          | 28.1          |
| Interstitial nephritis            | 8.6           | 7.8           |
| Congenital nephropathy            | 6.4           | 1.9           |
| Other renal disease               | 1.6           | 1.4           |
| Unknown aetiology                 | 17.5          | 15.8          |
| Concomitant diseases, %           |               |               |
| Hypertension                      | 87.4          | 80.7          |
| Diabetes                          | 41.9          | 46.6          |
| Chronic heart disease             | 40.5          | 55.3          |
| Peripheral arterial disease       | 23.7          | 29.5          |
| Retinopathy                       | 20.7          | 20.1          |
| Polyneuropathy                    | 18.6          | 21.5          |
| Cerebrovascular insufficiency     | 13.5          | 23.5          |
| Pulmonary disease                 | 8.5           | 7.3           |
| Malignancy                        | 7.4           | 9.2           |
| Amputation                        | 6.3           | 4.5           |

aAssuming proportionally distributed events in missing cases when calculating percentages.
dialysis-associated complications (see Table 2) and haemoglobin (Hb) levels were assessed monthly. The following data were collected every 3 months: dialysis adequacy, routine haematological and serum biochemical parameters, hospitalizations and co-morbidities (see Tables 3 and 4). The comedication and number of transfusions were documented every 6 months. To describe and compare morbidity, the age-adjusted (1 point for each decade over the age of 40 years) Charlson comorbidity index (CCI) was used, with higher scores indicating greater comorbidity [11]. A strong correlation between the age-adjusted CCI score and mortality in maintenance RRT patients has been demonstrated [12]. The minimum score of all patients was 2 due to terminal renal failure. The minimum value in the elderly cohort was 6 as a result of the age adjustment. Furthermore, QoL parameters were evaluated at baseline and at 12 and 24 months in a subcohort of 68 participating centres (74%) by means of the Functional Assessment of Chronic Illness Therapy (FACT) Anaemia score (FACT-An, version 4; see www.facit.org for details) [13]. Questions Results were measured on a 5-point scale (0–4 points). The total score was obtained by summing the four subscale scores for physical (PWB), social/family (SWB), emotional (EWB) and functional (FWB) well-being (equivalent to the FACT-General; 27 items) and adding the score for the anaemia subscale (AnS; 20 items). Score ranges were 0–24 (EWB; 6 items), 0–28 (PWB, SWB and FWB; 7 items each) and 0–80 (AnS), with higher scores indicating a better rehabilitation (total of 47 questions; maximum FACT-An score 188). On negatively phrased questions scores were reversed, and in case of skipped questions, the value was prorated using the score average in the individual subscale. The Trial Outcome Index (TOI) as an index of physical and functional outcome was determined by summing the PWB, FWB and AnS subscales. Assessment was performed by means of a paper case report form on a voluntary basis (24 centres opted out). In addition to QoL parameters, the need for general nursing care was assessed at baseline. This is a technical term of disability in the German health care system to evaluate nursing staff requirements for inpatient care. Patients in levels A1–A3 are in need of basic support (personal hygiene, nutrition, mobility) for an average of 1, 2 or 3 h/day, respectively. Depending on the amount of additional special care needed (e.g. infusions, wound dressings, assistance with medication intake), the calculated range of nursing staff required is 52–88 (A1), 98–134 (A2) and 178–215 (A3), respectively. For the sample size calculation, a 20% difference of target variables was regarded as clinically relevant and should be detectable (even in subgroups) with a precision <20% [length of 95% confidence interval (CI)]. Assuming a dropout rate of 20%, this leads to a total population size of 2500 patients (with at least one documented visit).

Data management and statistical analyses

Data tracking was performed using log files that were read into a global database using a validated check routine. In case of inconsistencies, a query was sent to the responsible clinical site. Outliers outside of the 4 standard deviation (SD) region of the mean were eliminated in case the query was left unanswered. Statistical analyses were performed as an explorative evaluation with descriptive interpretation of differences between the subgroups. Calculations were performed within the SAS software version 9.1 (SAS Institute, Cary, NC, USA) on a Microsoft Windows operating system (Microsoft, Unterschleissheim, Germany). Where applicable, subgroup analyses were supplemented by multivariate procedures (logistic regression, Cox regression) to identify relevant predictors of the target variables and to study the influence of cofactors. Hazard ratios (HRs) were used to describe the results of the Cox analysis.

**Table 2. Type of baseline treatment parameters and dialysis-associated complications during the observation period**

|                  | Age <75 years | Age ≥75 years |
|------------------|---------------|---------------|
| Median dialysis dose (h/week) | 12.0          | 12.0          |
| Frequency of dialysis, %        |                |               |
| 2× per week           | 4.4           | 7.2           |
| 3× per week           | 93.5          | 91.3          |
| 4× per week           | 1.3           | 1.5           |
| Other                | 0.8           | –             |
| Median blood flow (mL/min)   | 280           | 250           |
| Median ultrafiltration rate (mL/h) | 600       | 500           |
| Patients with dialysis-associated complications, % | 53.8          | 60.4          |
| Type of complication, %      |                |               |
| Muscle cramps          | 25.2          | 30.3          |
| Hypertension           | 21.9          | 31.5          |
| Hypertension           | 19.5          | 16.6          |
| Itching               | 12.0          | 11.8          |
| Polyneuropathic pain    | 10.8          | 11.4          |
| Pain in bones or joints | 9.6           | 12.2          |
| Skin alterations       | 5.9           | 8.4           |
| Allergic reactions     | 1.9           | 1.5           |
| Carpal tunnel syndrome  | 1.3           | 1.9           |
| Others                | 4.6           | 4.1           |

*Assuming proportionally distributed events in missing cases when calculating percentages.

**Table 3. Comorbidity, hospitalization and survival**

|                  | Age <75 years | Age ≥75 years |
|------------------|---------------|---------------|
| Baseline Charlson comorbidity index, % |                |               |
| 2–4              | 36.2          | –             |
| 5–6              | 38.9          | 40.3          |
| ≥7               | 24.9          | 59.7          |
| Patients with hospitalization(s) in 24 months, % | 33.3          | 34.0          |
| Median hospital days per year | 8.9           | 12.3          |
| Survival (Kaplan-Meier estimators) |                |               |
| Month 12         | 0.916         | 0.808         |
| Month 24         | 0.829         | 0.628         |
| Survival (Kaplan-Meier estimators) |                |               |
| Public centres   |                |               |
| Month 12         | 0.968         | 0.915         |
| Month 24*        | 0.899         | 0.765         |
| Private centres  |                |               |
| Month 12         | 0.967         | 0.930         |
| Month 24*        | 0.910         | 0.753         |
| *Comparison of survival (log-rank test) | P = 0.39      | P = 0.94      |
| Yearly mortality rate, % | Elderly       | DZA* 2006     |
| <50 years        | 2.00          | 0.10          |
| 50–59 years      | 4.80          | 0.52          |
| 60–69 years      | 8.78          | 1.16          |
| 70–79 years      | 13.1          | 3.12          |
| ≥80 years        | 19.0          | 13.6          |

*German Centre of Gerontology (DZA: Deutsches Zentrum fuer Altersfragen).
Table 4. Treatment quality (mean values), comedication* and QoL parameters (maximum likelihood estimates)

|                          | Month | Age <75 years | Age ≥75 years |
|--------------------------|-------|---------------|---------------|
| **eKt/V**                |       | 0             | 1.32          | 1.29          |
|                          |       | 12            | 1.37          | 1.33          |
|                          |       | 24            | 1.46          | 1.40          |
| Change from Bl.          |       |               | P < 0.0001    | P < 0.0001    |
| **Haemoglobin (g/dL)**   |       | 0             | 11.6          | 11.8          |
|                          |       | 12            | 11.9          | 11.8          |
|                          |       | 24            | 11.8          | 11.8          |
| Change from Bl.          |       |               | P < 0.0001    | P = 0.94      |
| **Corrected total calcium (mmol/L)** |       | 0             | 2.30          | 2.31          |
|                          |       | 12            | 2.28          | 2.30          |
|                          |       | 24            | 2.26          | 2.28          |
| Change from Bl.          |       |               | P < 0.0001    | P < 0.01      |
| **Phosphate (mmol/L)**   |       | 0             | 1.90          | 1.72          |
|                          |       | 12            | 1.86          | 1.72          |
|                          |       | 24            | 1.81          | 1.72          |
| Change from Bl.          |       |               | P < 0.0001    | P = 1.00      |
| Corrected calcium × phosphate product (mmol²/L²) |       | 0             | 4.41          | 4.02          |
|                          |       | 12            | 4.23          | 3.98          |
|                          |       | 24            | 4.13          | 3.93          |
| Change from Bl.          |       |               | P < 0.0001    | P = 0.12      |
| **iPTH (pmol/L)**        |       | 0             | 14.7          | 13.3          |
|                          |       | 12            | 16.1          | 14.2          |
|                          |       | 24            | 17.1          | 17.1          |
| Change from Bl.          |       |               | P < 0.0001    | P < 0.0001    |
| **Albumin (g/L)**        |       | 0             | 40.1          | 38.7          |
|                          |       | 12            | 40.5          | 39.1          |
|                          |       | 24            | 40.6          | 38.9          |
| Change from Bl.          |       |               | P = 0.005     | P = 0.50      |
| **HbA1c (%)**            |       | 0             | 6.16          | 6.07          |
|                          |       | 12            | 6.09          | 5.94          |
|                          |       | 24            | 6.03          | 5.96          |
| Change from Bl.          |       |               | P < 0.0001    | P < 0.05      |
| **Transferrin saturation (%)** |     | 0             | 23.9          | 23.8          |
|                          |       | 12            | 25.7          | 24.5          |
|                          |       | 24            | 24.7          | 24.4          |
| Change from Bl.          |       |               | P < 0.05      | P = 0.36      |
| **Ferritin (µg/L)**      |       | 0             | 340           | 354           |
|                          |       | 12            | 476           | 485           |
|                          |       | 24            | 501           | 508           |
| Change from Bl.          |       |               | P < 0.0001    | P < 0.0001    |
| **CRP (mg/L)**           |       | 0             | 6.12          | 6.82          |
|                          |       | 12            | 5.95          | 6.49          |
|                          |       | 24            | 6.02          | 6.79          |
| Change from Bl.          |       |               | P = 0.66      | P = 0.96      |
| **BMI (kg/m²)**          |       | 0             | 26.4          | 25.6          |
|                          |       | 12            | 26.3          | 25.2          |
|                          |       | 24            | 26.1          | 25.0          |
| Change from Bl.          |       |               | P < 0.0001    | P < 0.0001    |
| **Weekly darbepoetin alfa dose (µg/week)** |     | 0             | 35.3          | 34.0          |
|                          |       | 12            | 32.1          | 31.5          |
|                          |       | 24            | 32.0          | 30.6          |
| **Antihypertensive agents (excluding diuretics)** |     | 0             | 87.3%         | 84.4%         |
|                          |       | 12            | 84.6%         | 82.7%         |
|                          |       | 24            | 83.6%         | 81.6%         |
| **Diuretics**            |       | 0             | 69.3%         | 74.0%         |
|                          |       | 12            | 63.1%         | 68.8%         |
|                          |       | 24            | 59.0%         | 63.7%         |
| **Cardiac glycosides**   |       | 0             | 8.6%          | 14.1%         |
|                          |       | 12            | 9.3%          | 13.2%         |
|                          |       | 24            | 10.6%         | 13.5%         |
| **Iron therapy**         |       | 0             | 77.0%         | 79.3%         |
|                          |       | 12            | 69.2%         | 70.9%         |
|                          |       | 24            | 69.5%         | 70.8%         |

Table continues
In all other cases, odds ratios (ORs) were determined to compare relative differences without any time dependency. Time trends were investigated by performing conventional longitudinal analyses with maximum likelihood estimators to provide valid results in case of isolated missing values or dropouts classified as missing completely at random (MCAR) or missing at random (MAR), respectively. Life table analyses were performed for evaluation of mortality by applying Kaplan–Meier estimators and related plots. Different strata were compared with the log-rank test. In addition, death rates of the study population were compared with data from the German Centre of Gerontology [Deutsches Zentrum fuer Altersfragen (DZA)] [14].

**Results**

**Study population**

A total of 2507 haemodialysis patients (45% female, 55% male) 19–98 years of age (median 70 years) in 76 private (for-profit) and 16 public (not-for-profit) dialysis centres were enrolled in the study.

| Month | Age <75 years | Age ≥75 years |
|-------|---------------|---------------|
| 0     | 81.9%         | 69.1%         |
| 12    | 82.0%         | 73.3%         |
| 24    | 82.4%         | 73.6%         |
| 0     | 62.6%         | 60.1%         |
| 12    | 62.6%         | 63.7%         |
| 24    | 63.5%         | 69.5%         |
| 0     | 20.4          | 18.7          |
| 12    | 20.2          | 18.2          |
| 24    | 19.6          | 17.3          |
| Change from BL | –3.9% | –7.5% |
| 0     | 21.0          | 20.8          |
| 12    | 20.8          | 20.5          |
| 24    | 20.4          | 20.4          |
| Change from BL | –2.9% | –1.9% |
| 0     | 17.1          | 16.4          |
| 12    | 17.2          | 16.2          |
| 24    | 16.9          | 15.8          |
| Change from BL | –1.2% | –3.7% |
| 0     | 16.0          | 14.5          |
| 12    | 15.9          | 14.0          |
| 24    | 15.4          | 12.6          |
| Change from BL | –3.8% | –13.1% |
| 0     | 35.5          | 30.9          |
| 12    | 35.0          | 30.5          |
| 24    | 34.3          | 29.3          |
| Change from BL | –3.4% | –5.2% |
| 0     | 109.9         | 101.1         |
| 12    | 108.9         | 99.2          |
| 24    | 106.3         | 95.2          |
| Change from BL | –3.6% | –5.8% |
| 0     | 74.4          | 70.3          |
| 12    | 73.9          | 68.7          |
| 24    | 72.0          | 65.9          |
| Change from BL | –3.2% | –6.3% |
| 0     | 71.9          | 63.9          |
| 12    | 71.0          | 62.5          |
| 24    | 69.3          | 59.1          |
| Change from BL | –3.6% | –7.5% |

*aAssuming proportionally distributed events in missing cases when calculating percentages.
*bEquilibrated Kt/V was computed according to the double pool Daugirdas equation for arteriovenous and venovenous accesses. Blood samples were taken according to the European Best Practice Guidelines for Haemodialysis after a long interval of the respective dialysis regimen [9, 10].

*cRelative mean change from baseline (BL) to month 24 (negative values denote a decrease).
The median haemodialysis vintage at baseline was 19.2 months (95% CI 17.6–20.8). A total of 20%, 68% and 12% of the study population were registered in the years 2004, 2005 and 2006, respectively. At each assessment after baseline, documentation was complete in 94% of cases (median value over complete study period) and for 63% of survivors at 24 months complete documentation for all study appointments (n = 25) was provided. FACIT scores were sampled in a subcohort of 1373 patients (55%).

Withdrawal occurred in 9.3% (n = 232) due to renal transplantation (n = 92), change of dialysis centre (n = 52), termination of RRT (n = 25), cessation of darbepoetin alfa therapy (n = 25) or other reasons (n = 38). The median follow-up time was 24.2 months.

**Baseline demographic data**

At study entry, 1711 patients (68%) were <75 years and 796 (32%) were ≥75 years of age (median 66 and 79 years, respectively). At enrolment, the younger cohort showed a longer duration of RRT, a higher percentage of male patients and a higher frequency of native arteriovenous (AV) fistulas (see Table 1). The distribution of the age-adjusted CCI values is demonstrated in Table 3. The level of general nursing care was reported as degree 2 or 3 in 17.4 and 4.7% in the older and younger cohort, respectively.

**Mortality**

The overall mortality rate in the 24-month observation period was 21.8% (n = 547), with rates of 34.7 and 15.8% for patients ≥75 and <75 years of age, respectively. The main causes of death were heart failure (23%), septicemia/infection (17%), myocardial infarction (10%), stroke (7.7%) and malignancies (6.0%). The median haemodialysis vintage at study enrolment did not differ substantially between survivors and non-survivors (18.8 versus 21.9 months, respectively) and was lower in the older patient cohort (see Table 1). The comparison with data from the national age-matched background population (DZA: Deutsches Zentrum fuer Altersfragen) revealed an average difference in the yearly mortality rate of approximately +6–7% (absolute value) (17.4 versus 11.2% in the cohort ≥75 years and 7.9 versus 1.1% in the cohort <75 years) (see Figure 1) [14]. Consequently, the relative mortality risk for the younger haemodialysis population was disproportionately high (OR 8.4 for patients <75 years). The Kaplan–Meier estimate for the 24-month survival probability for elderly patients was 62.8%, compared to 82.9% for patients in the younger age group (log-rank test P < 0.0001; see Table 3). No significant differences were observed regarding the survival probability of patients in private versus public dialysis centres (see Table 3). The mortality rate of patients with a CCI ≤6 was 14.7% (<75 years:

---

**Fig. 1.** Age-specific yearly mortality rate of haemodialysis patients in the ELDERLY study compared with the German background population (DZA: Deutsches Zentrum fuer Altersfragen). Detailed numbers are demonstrated at the bottom of Table 3.

**Fig. 2.** Kaplan–Meier estimates for survival stratified by the baseline FACT-An score. The survival probability at the end of the observation period was 0.89, 0.78 and 0.64, respectively.
12.1%; ≥75 years: 24.9%) versus 34.5% for patients with a CCI ≥7 (<75 years: 27.0%; ≥75 years: 41.3%). Multivariate Cox regression analyses with the observation period as the target variable identified three variables that were associated with a mortality risk reduction: baseline Hb >10 g/dL [HR 0.8 (95% CI 0.6–1.0)] as well as a higher (＞1st quartile) body mass index (BMI) [HR 0.7 (95% CI 0.6–0.9)] and higher (＞1st quartile) FACT-An score [HR 0.7 (95% CI 0.6–0.9)]. Increasing age of patients [≥75 years] [HR 1.7 (95% CI 1.3–2.3)], higher levels (>1) of nursing care [HR 1.3, (95% CI 1.1–1.6)], the presence of cardiovascular diseases [HR 1.5 (95% CI 1.1–2.0)] or a high range of comorbid conditions (CCI ≥ 7) [HR 1.5 (95% CI 1.1–2.0)] increased the mortality risk by at least 10%. Adding information from the QoL assessment (see Figure 2), the baseline FACT-An score was identified as a powerful predictor of survival probability [HR 0.7 for patients in the highest quartile (95% CI 0.6–0.9), P = 0.0004].

Hospitalizations
During the 24-month observation period, 33–34% of all patients were hospitalized at least once, with no substantial difference between the two age groups (see Table 3). In each time interval of 3 months at least one hospitalization occurred in 8.4% of all patients (average value of all visits). The median number of all-cause hospital days per patient-year for the total population was 9.7 (95% CI 8.6–11.0). Elderly patients were hospitalized for a median of 12.3 days (95% CI 9.7–15.6) compared with 8.9 days (95% CI 7.8–9.9) in the younger cohort (see Table 3). In 93% of all cases the duration of the hospital stay was <30 days.

Quality of life
Limited self-care, which was defined as a general nursing care level >1 (>1.5 h of estimated support per day; see above) was present in 34% of patients ≥75 years of age and in 17% of patients in the younger cohort. The risk for an allocation to a care level >1 was more than twice as high for patients in the elderly cohort [OR 2.6 (95% CI 2.1–3.1)]. The QoL scores are demonstrated in Table 4 and Figure 3. A descriptive comparative analysis of the total patient population and the subgroup of patients with sampled QoL scores indicated the homogeneity of both groups with respect to age, gender, BMI, underlying disease, concomitant diseases, dialysis period, CCI and mortality. At baseline, the greatest differences between the two patient groups (in ascending order) were observed in the anaemia, physical and functional subscales. These three indices, reflected by the TOI score, also showed the greatest deterioration over the course of the observation period. The scores for EWB showed a moderate deterioration in both cohorts. Interestingly, the value for SWB was equal in both age groups at the end of the observation period due to a more pronounced decline in the younger cohort. The total score (FACT-An) decreased by 3.9% in 24 months (<3.6% and ~5.8% for the younger and older cohort, respectively) and was ~10% lower in the elderly subgroup at the end of the study period. To estimate the degree of information from each individual score, a pairwise correlation for the FACT-An score was performed. With the exception of the SWB subscale (Pearson correlation coefficient ρ = 0.46), all scores showed a strong positive correlation (ρ ≥ 0.80), which was highest for the 20-item anaemia subscale (ρ = 0.93) and the TOI (ρ = 0.97).

Treatment parameters and achievement of target levels
Vascular access using native vessels was used in 81.2% of patients ≥75 years of age versus 86.5% in the younger cohort (see Table 1), with rates of AV fistula thrombosis/occlusion of 2.2 and 3.2% per patient-year, respectively. The median administered darbepoetin alfa dose was 30 µg/week and did not differ between the two age groups. The achieved Hb levels were stable (see Table 4). Transfusions were documented in 8.4% of the total study population over the course of 24 months (7.7% in the age class <75 and 10.1% in the age class ≥75 years). Dialysis adequacy slightly increased during the observation period in both cohorts. The serum albumin level remained stable during the course of the study for both age groups and was lower in the older cohort (see Table 4).

Discussion
In recent years, the number of elderly patients with ESRD has steadily increased [1, 2]. There has been a discussion whether—compared with conservative management—dialysis improves the QoL in the elderly patient population, particularly because the survival benefit of commencing dialysis in this age group is
often reduced as a result of the considerable comorbidity and factors such as late referral [15–20]. A recent European survey shows a rate for conservative care of up to 15% in elderly patients with terminal renal failure [21]. The presence of severe comorbidities (particularly vascular dementia) and a low physical–functional status were important factors to withhold RRT. Patient preference was a key criterion underlying the significance of shared decision making. In particular, frailty is associated with poor outcomes in haemodialysis patients [7, 22–24]. Also, favourable results have been reported, especially for patients participating in geriatric rehabilitation programmes [8, 25–29]. Another point of discussion is whether the additional lifetime gained by conservatively managed elderly patients is considered rewarding by the patient [30, 31]. Hospital admissions, particularly if frequent and prolonged, impact all measured domains of QoL. Apart from emotional and social factors, hospitalizations are closely associated with further physical and functional deterioration, the need for long-term care and an increased mortality [24, 32]. In our study, the observed hospitalization rate (33–34% of patients in 24 months) did not differ significantly between the two age groups (see Table 3). The median yearly hospitalization time was—as expected—higher in elderly patients (12.3 versus 8.9 days/year), but lower compared with USRDS registry data [median of 15.5 days/year (adjusted); 2005 period prevalent patients ≥75 years] and considerably lower compared with some reports in the past (up to a median of 33.4 inpatient days per year of survival for patients ≥75 years of age) [1, 24]. Dialysis efficacy was high throughout the observation period and did not differ significantly between the two age groups or between treatments in private or public institutions. Contrary to the results of a study with USRDS data, no significant differences were observed with respect to mortality in private or public dialysis centres [33]. Three sessions per week was the standard therapy in elderly patients. While the prevalence of native arteriovenous fistulas is generally high in the European (and Japanese) dialysis population, this study also shows a high rate in the elderly patient cohort (>81%). The generally lower rate of native arteriovenous fistulas in elderly patients could be explained in part by the higher rate of native fistula failures due to the higher prevalence of diabetes and atherosclerotic disease [1, 34]. Current data suggest that prosthetic grafts are an adequate approach to vascular access in this population, while catheter placement should still be considered a last resort [35, 36].

During the 24-month observation period there was no major clinically relevant deterioration of parameters considered relevant for survival, such as serum albumin, phosphate control and BMI. In addition to the adequate control of these critical biochemical and biophysical factors, the elderly haemodialysis patients showed a high degree of social well-being. While the EWB was in general lower and reduced to a greater extent in the elderly cohort, the SWB score was the same in both age groups at the end of the observation period and a more pronounced decline was observed in younger patients (see regression line in Figure 3). In accordance with previous findings, the physical and functional status deteriorated more sharply in the elderly cohort [37]. The change in performance status over time is well reflected by the TOI as a summary index containing the physical (PWB) and functional (FWB) as well as the symptom subscale scores (AnS) (see bottom of Figure 3). Prior studies have also shown that in particular the functional status of the elderly haemodialysis patient worsens notably despite treatment of uraemia, especially when significant comorbid conditions were present [7, 38]. On the other hand, there is evidence that an acceptable functional status can be maintained until the very late phase in conservatively managed elderly ESRD patients and that a palliative ‘no dialysis’ approach may be more suitable for a certain subset of patients [39, 40]. Murtagh et al. [41] reported 2-year survival rates of up to 66% for ESRD patients managed without RRT and that functional status declined steeply only in the last month of life.

The present study documents that the mortality rate of elderly haemodialysis patients was not exceedingly higher compared with the age-matched background population (absolute increase of the yearly mortality rate of 6.2% for the cohort ≥75 years; see Figure 1). The Kaplan–Meier estimate for survival at the end of the 24-month observation period was 62.8% for patients ≥75 years and comparable to the results reported for the European cohort in the Dialysis Outcomes and Practice Patterns Study III (prevalent patients 2005–2007) [42]. The adjusted 2-year survival rates for incident (and therefore non-selected) patients from
other registries are lower, as expected, and range from 54 to 59% [2, 18, 43]. A smaller study from Murtagh et al. [16] comparing elderly CKD stage 5 patients managed conservatively or with haemodialysis showed 2-year survival rates of 47 and 76%, respectively. The survival advantage of dialysed patients was lost in patients with a high level of comorbidity, especially among patients with ischaemic heart disease. A recent single-centre retrospective study showed no significant survival advantage among patients ≥80 years of age choosing RRT over a conservative approach [44]. Several parameters have been identified to be associated with a better survival of elderly patients on dialysis [18, 26, 45–49]. In the present study the survival probability was closely linked to the baseline 47-item FACT-An score (see Figure 2). A close correlation of the total FACT-An score with the anaemia subscale (AnS) containing 20 quickly assessable items was demonstrated (Pearson correlation coefficient r = 0.93). Elderly patients with a high QoL had a higher survival probability than patients in the younger cohort with poor overall QoL (FACT-An ≤1st quartile; see Figure 4). Although available in daily clinical routine, it is still a matter of debate whether to use predictive outcome models as part of clinical decision making.

The results from the current study are certainly limited due to its observational nature and the possible selection bias. All patients were on erythropoietin therapy and survived the crucial initiation period of haemodialysis. Consequently, this study cannot provide information on mortality in the early months after initiation of RRT (the median haemodialysis vintage was roughly 1.5 years) and all estimates concerning survival and QoL should only be regarded as an upper limit. Furthermore, patients with considerable frailty or cognitive impairment were less likely to be included, although the trial did not set up limitations with regard to comorbid conditions. Regarding the possible additional selection of healthier patients by sampling QoL parameters on a voluntary basis, the performed descriptive comparative analysis indicated that the QoL subgroup was representative of the total study population. The geographical distribution of centres did not show specific clusters. We considered the increasing number of missing values and dropouts as an important reason for bias and therefore determined point estimators with classification of missing values as MCAR and dropouts as MAR (see statistic section for details). Erythropoietin, which was administered to all study patients, does not seem to have a significant impact of missing values as MCAR and dropouts as MAR (see statistical analyses). The authors would like to particularly thank him for his constant support. The investigators would also like to express their special gratitude to the patients and staff of the participating dialysis centres for their valuable contribution to this study.

Conflict of interest statement

U.F. has been employed by Amgen® Germany, the sponsor of the study, since 1999. All other authors have no conflicts of interest in relation to the publication of this article.

References

1. United States Renal Data System. USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2011
2. ERA-EDTA Registry. ERA-EDTA Registry Annual Report 2009. Amsterdam, The Netherlands: Academic Medical Center, Department of Medical Informatics, 2011
3. ANZDATA Registry. ANZDATA Registry Report 2010. Adelaide, South Australia: Australia and New Zealand Dialysis and Transplant Registry, 2011
4. Kurella M, Covinsky KE, Collins AJ et al. Octogenarians and nonagenarians starting dialysis in the United States. Ann Intern Med 2007; 146: 177–183
5. De Nicola L, Minutolo R, Chiodini P et al. The effect of increasing age on the prognosis of non-dialysis patients with chronic kidney disease receiving stable nephrology care. Kidney Int 2012; 82: 482–488
6. Dalrymple LS, Katz R, Kestenbaum B et al. Chronic kidney disease and the risk of end-stage renal disease versus death. J Gen Intern Med 2011; 26: 379–385
7. Kurella Tamura M, Covinsky KE, Chertow GM et al. Functional status of elderly adults before and after initiation of dialysis. N Engl J Med 2009; 361: 1539–1547
8. Lamping DL, Constantinovic N, Roderick P et al. Clinical outcomes, quality of life, and costs in the North Thames Dialysis Study of elderly people on dialysis: a prospective cohort study. Lancet 2000; 356: 1543–1550
9. Daugirdas JT. Simplified equations for monitoring Kt/V, PCrN, eKt/V, and ePCRn. Adv Ren Replace Ther 1995; 2: 295–304
10. European Best Practice Guidelines Expert Group on Hemodialysis, European Renal Association. Section II. Haemodialysis adequacy. Nephrol Dial Transplant 2002; 17(Suppl 7): 16–31
11. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373–383
12. Di Lorio B, Cillo N, Cirillo M et al. Charlson Comorbidity Index is a predictor of outcomes in incident hemodialysis patients and correlates with phase angle and hospitalization. Int J Artif Organs 2004; 27: 330–336
13. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997; 34(3 Suppl 2): 13–19
14. German Center of Gerontology (DZA). Statistical Information System GeroStat: Age specific death rates 2008. Data origin:
15. Carson RC, Juszczak M, Davenport A et al. Is maximum conservative management an equivalent treatment option to dialysis for elderly patients with significant comorbid disease? Clin J Am Soc Nephrol 2009; 4: 1611–1619

16. Murtagh FE, Marsh JE, Donohoe P et al. Dialysis or not? A comparative survival study of patients over 75 years with chronic kidney disease stage 5. Nephrol Dial Transplant 2007; 22: 1955–1962

17. Jassal SV, Watson D. Dialysis in late life: benefit or burden. Clin J Am Soc Nephrol 2009; 4: 2008–2012

18. Foote C, Ninomiya T, Gallagher M et al. Survival of elderly dialysis patients is predicted by both patient and practice characteristics. Nephrol Dial Transplant 2012; 27: 3581–3587

19. Schwenger V, Morath C, Hofmann A et al. Late referral—a major cause of poor outcome in the very elderly dialysis patient. Nephrol Dial Transplant 2006; 21: 962–967

20. Leimbach T, Kron J, Czerny J et al. Hemodialysis in patients over 80 years. Nephron 2015; 129: 214–218

21. van de Luitjegaarden MW, Noordzij M, van Biesen W et al. Conservative care in Europe—nephrologists’ experience with the decision not to start renal replacement therapy. Nephrol Dial Transplant 2013; 28: 2604–2612

22. Li M, Tomlinson G, Naglie G et al. Geriatric comorbidities, such as falls, confer an independent mortality risk to elderly dialysis patients. Nephrol Dial Transplant 2008; 23: 1396–1400

23. Johansen KL, Chertow GM, Chin C et al. Significance of frailty among dialysis patients. J Am Soc Nephrol 2007; 18: 2960–2967

24. Munshi SK, Vijayakumar N, Taub NA et al. Outcome of renal replacement therapy in the very elderly. Nephrol Dial Transplant 2001; 16: 128–133

25. Basic-Jukic N, Kes P, Juric I et al. Octogenarians on hemodialysis: a prospective study. Arch Gerontol Geriatr 2008; 47: 19–24

26. Jassal SV, Trpeski L, Zhu N et al. Changes in survival among elderly patients initiating dialysis from 1990 to 1999. CMAJ 2007; 177: 1033–1038

27. Jassal SV, Chiu E, Li M. Geriatric hemodialysis rehabilitation care. Adv Chronic Kidney Dis 2008; 15: 115–122

28. Li M, Porter E, Lam R et al. Quality improvement through the introduction of interdisciplinary geriatric hemodialysis rehabilitation care. Am J Kidney Dis 2007; 50: 90–97

29. Anding K, Bar T, Trponjak-Hennig J et al. A structured exercise programme during haemodialysis for patients with chronic kidney disease: clinical benefit and long-term adherence. BMJ Open 2015; 5: e008709

30. Apostolou T. Quality of life in the elderly patients on dialysis. Int Urol Nephrol 2007; 39: 679–683

31. Kutner NG, Jassal SV. Quality of life and rehabilitation of elderly dialysis patients. Semin Dial 2002; 15: 107–112

32. Lo D, Chiu E, Jassal SV. A prospective pilot study to measure changes in functional status associated with hospitalization in elderly dialysis-dependent patients. Am J Kidney Dis 2008; 52: 956–961

33. Zhang Y, Cotter DJ, Thamer M. The effect of dialysis chains on mortality among patients receiving hemodialysis. Health Serv Res 2010; 46: 747–767

34. Hod T, Desilva RN, Patibandla BK et al. Factors predicting failure of AV ‘fistula first’ policy in the elderly. Hemodial Int 2014; 18: 507–515

35. Combe C, Berard X. Dialysis: ‘catheter last’ not ‘fistula first’ in elderly patients. Nat Rev Nephrol 2013; 9: 632–634

36. DeSilva RN, Patibandla BK, Vin Y et al. Fistula first is not always the best strategy for the elderly. J Am Soc Nephrol 2013; 24: 1297–1304

37. Cook WL, Jassal SV. Functional dependencies among the elderly on hemodialysis. Kidney Int 2008; 73: 1289–1295

38. Jassal SV, Chiu E, Hladunewich M. Loss of independence in patients starting dialysis at 80 years of age or older. N Engl J Med 2009; 361: 1612–1613

39. Murtagh FE, Cohen LM, Germain MJ. The ‘no dialysis’ option. Adv Chronic Kidney Dis 2011; 18: 443–449

40. Da Silva-Gane M, Farrington K. Supportive care in advanced kidney disease: patient attitudes and expectations. J Ren Care 2014; 40(Suppl 1): 30–35

41. Murtagh FE, Addington-Hall JM, Higginson IJ. Dialysis or not? A comparison of dialysis with no dialysis options for end-stage renal disease. J Am Soc Nephrol 2003; 14: 384–390

42. Canaud B, Tong L, Tentori F et al. Clinical practices and outcomes in elderly hemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Clin J Am Soc Nephrol 2011; 6: 1651–1662

43. Steenkamp R, Castledine C, Feest T et al. UK Renal Registry 13th Annual Report (December 2010): Chapter 2: UK RRT prevalence in 2009: national and centre-specific analyses. Nephron Clin Pract 2011; 119(Suppl 2): c27–c52

44. Verberne WR, Geers ABM, Jellemza WT et al. Comparative survival among older adults with advanced kidney disease managed conservatively versus with dialysis. Clin J Am Soc Nephrol 2016; 11: 633–640

45. Madziaska K, Weyde W, Krajewksa M et al. Elderly dialysis patients: analysis of factors affecting long-term survival in 4-year prospective observation. Int Urol Nephrol 2012; 44: 955–961

46. Couchoud C, Labeewo M, Moranne O et al. A clinical score to predict 6-month prognosis in elderly patients starting dialysis for end-stage renal disease. Nephrol Dial Transplant 2009; 24: 1553–1561

47. Madziaska K, Weyde W, Gosek K et al. Serum levels of proANP and albumin are independent predictors of mortality in the high-risk patients (elderly and diabetics) treated by haemodialysis (HD) and continuous peritoneal dialysis in 4-year prospective observation. Nephrol Dial Transplant 2010; 25: 3800–3801

48. Verdalles U, Abad S, Aragoncillo I et al. Factors predicting mortality in elderly patients on dialysis. Nephron Clin Pract 2010; 115: c28–c34

49. de Jonge P, Ruinemans GM, Huyse FJ et al. A simple risk score predicts poor quality of life and non-survival at 1 year follow-up in dialysis patients. Nephrol Dial Transplant 2003; 18: 2622–2628

50. Collister D, Komenda P, Hiebert B et al. The effect of erythropoietin-stimulating agents on health-related quality of life in anemia of chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2016; 164: 472–478

51. Hemmelgarn BR, Manns BJ, Quan H et al. Adapting the Charlson Comorbidity Index for use in patients with ESRD. Am J Kidney Dis 2003; 42: 125–132